Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Minireview: update on incretin biology: focus on glucagon-like peptide-1 Brubaker PLEndocrinology 2010[May]; 151 (5): 1984-9The incretin hormone, glucagon-like peptide-1 (GLP-1), is now being used in the clinic to enhance insulin secretion and reduce body weight in patients with type 2 diabetes. Although much is already known about the biology of GLP-1, much remains to be understood. Hence, this review will consider recent findings related to the potential for enhancing endogenous levels of GLP-1 through selective use of secretagogues and the beneficial cardiovascular, neuroprotective, and immunomodulatory effects of GLP-1, as well as the possible effects of GLP-1 to enhance beta-cell growth and/or to induce pancreatitis or thyroid cancer. Finally, the potential for molecular medicine to enhance the success of GLP-1 therapy in the clinic is considered. A better understanding of the fundamental biology of GLP-1 may lead to new therapeutic modalities for the clinical use of this intestinal hormone.|Animals[MESH]|Apoptosis/drug effects[MESH]|Diabetes Mellitus, Type 2/drug therapy/*metabolism[MESH]|Glucagon-Like Peptide 1/*metabolism/therapeutic use[MESH]|Humans[MESH]|Hypoglycemic Agents/metabolism/pharmacology[MESH]|Incretins/*metabolism/pharmacology[MESH]|Insulin-Secreting Cells/cytology/drug effects/*metabolism[MESH]|Receptors, Glucagon/agonists/metabolism[MESH] |
